← Back to Search

CAR T-cell Therapy

CAR T cells for Non-Hodgkin's Lymphoma

Phase 1 & 2
Waitlist Available
Led By Jun Zhu, MD
Research Sponsored by Peking University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years.
Awards & highlights

Study Summary

Currently, a majority of lymphomas cannot be cured by standard chemo-radiotherapy. Cluster of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 represents a very attractive target for chimeric antigen receptor (CAR)-based immune cell therapy. This study will evaluate a novel 4th generation CD30 CAR engineered with a self-withdrawal mechanism (FKBP-iCasp9) for both efficacy and safety evaluation in lymphoma patients.

Eligible Conditions
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients with adverse events.
Secondary outcome measures
Response rates to the 4th generation CAR T cells.
Survival time of Anti-CD30 CAR T cells in vivo.
Survival time of the patients.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CAR T cellsExperimental Treatment1 Intervention
Autologous 4th generation anti-CD30 CAR T cells

Find a Location

Who is running the clinical trial?

Peking UniversityLead Sponsor
436 Previous Clinical Trials
1,053,238 Total Patients Enrolled
University of FloridaOTHER
1,342 Previous Clinical Trials
715,650 Total Patients Enrolled
Jun Zhu, MDPrincipal InvestigatorPeking University Cancer Hospital & Institute
12 Previous Clinical Trials
823 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Jun Zhu 2014. "CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02274584.
All > Scar
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top